TLN1 and acute myeloid leukemia: In conclusion, TLN1 is a potential prognostic and therapeutic biomarker of AML, and it can affect the immune microenvironment to promote the proliferation of AML cells and inhibit differentiation and regulate multiple signal pathways in hematologic malignancies.